Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026)
Amylyx Pharmaceuticals' (AMLX) quarterly Income from Continuing Operations came in at 90950000.0 in Q1 2026, down 153.29% year-on-year from 170659576.19 in Q1 2025, and down 175.61% quarter-over-quarter from 32999000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 90950000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 153.29% year-over-year to 90950000.0 in Q1 2026; TTM through Mar 2026 was 199778000.0, a 28.23% decrease from a year earlier, with the FY2025 full-year figure at 144735000.0, up 39.36% from the prior year.
- Income from Continuing Operations slipped to 90950000.0 in Q1 2026 per AMLX's latest filing, from 32999000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 25510000.0 in Q4 2024 and bottomed at 118793000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 41443000.0 (2025), against an average of 36861117.65.
- Biggest YoY gain for Income from Continuing Operations was 845.87% in 2024; the steepest drop was 7652.0% in 2024.
- Year by year, Income from Continuing Operations stood at 43807000.0 in 2022, then surged by 106.16% to 2697000.0 in 2023, then surged by 845.87% to 25510000.0 in 2024, then plunged by 229.36% to 32999000.0 in 2025, then plunged by 175.61% to 90950000.0 in 2026.
- Per Business Quant, the three latest AMLX Income from Continuing Operations figures stand at 90950000.0 (Q1 2026), 32999000.0 (Q4 2025), and 34386000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Amylyx Pharmaceuticals | 2.01 Bn | 2.01 Bn | - | -90.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.95 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Sep 30, 2025 | -34.39 Mn |
| Jun 30, 2025 | -41.44 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Sep 30, 2024 | -72.70 Mn |
| Jun 30, 2024 | -72.70 Mn |
| Mar 31, 2024 | -118.79 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 20.89 Mn |
| Jun 30, 2023 | 22.07 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | -43.81 Mn |
| Sep 30, 2022 | -53.76 Mn |
| Jun 30, 2022 | -54.09 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -23.14 Mn |
| Jun 30, 2021 | -21.92 Mn |